Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Hepatitis

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 30 articles:
HTML format



Single Articles


    May 2025
  1. GANDHI K, Vijay Y, Page K, Dahari H, et al
    Challenges in coverage of future hepatitis C vaccines: Review and potential solutions.
    Vaccine. 2025;59:127256.
    PubMed     Abstract available


  2. HUNG SH, Torres JL, Chen F, Giang E, et al
    Antigenic and EM characterization of the Chiron experimental hepatitis C virus vaccine.
    Vaccine. 2025;58:127239.
    PubMed     Abstract available


    April 2025
  3. WIBOWO DP, Chalid MT, Rasyak MR, El Khobar KE, et al
    Characteristics of hepatitis B virus surface protein and occult hepatitis B infection in infants with immunoprophylaxis failure from Indonesia.
    Vaccine. 2025;56:127130.
    PubMed     Abstract available


  4. WANG F, Zheng J, Qiu F, Yang Y, et al
    Long-term effectiveness of vaccination for prevention of hepatitis B virus mother-to-child transmission in Yunnan, China.
    Vaccine. 2025;54:127128.
    PubMed     Abstract available


    March 2025
  5. OKOLI GN, Grossman Moon A, Soos AE, Neilson CJ, et al
    Hepatitis B vaccination initiation and vaccination series completion: An in-depth systematic evidence review, with meta-analysis of associations with individual socioeconomic and health-related factors.
    Vaccine. 2025;55:127051.
    PubMed     Abstract available


  6. VYSOTSKAYA V, Gassowski M, Kasper A, Gasich E, et al
    Hepatitis B serosurvey to validate the achievement of regional hepatitis B control targets in Belarus.
    Vaccine. 2025;55:127058.
    PubMed     Abstract available


  7. KANG M, Marks KM, Cox AL, Sherman KE, et al
    An efficient vaccine clinical trial: ACTG A5379 hepatitis B vaccine trial in persons with HIV.
    Vaccine. 2025;55:127028.
    PubMed     Abstract available


  8. GHARPURE R, Vegvari C, Abdissa A, Alimi Y, et al
    Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4-5 June 2024.
    Vaccine. 2025;54:126860.
    PubMed     Abstract available


    January 2025
  9. JIANG Y, Luo Y, Xiao X, Li X, et al
    Global, regional, and national burdens of vaccine-preventable infectious diseases with high incidence among middle-aged and older adults aged 55-89 years from 1990 to 2021: Results from the global burden of disease study 2021.
    Vaccine. 2025;49:126786.
    PubMed     Abstract available


  10. KHETSURIANI N, Tursunova D, Kasimova R, Sharapov S, et al
    Prevalence of chronic hepatitis B virus infection among children in Uzbekistan: Impact of vaccination.
    Vaccine. 2025;48:126743.
    PubMed     Abstract available


  11. CHIU CY, Sampathkumar P, Brumble LM, Vikram HR, et al
    Optimizing hepatitis B virus seroprotection in thoracic organ transplantation: The role of HepB-CpG (Heplisav-B) vaccination schedule.
    Vaccine. 2025;47:126705.
    PubMed     Abstract available


  12. SEO H, Kim BJ, Oh J, Jung S, et al
    Protection against tuberculosis by vaccination of secreted chorismate mutase (Rv1885c) combined with a hepatitis B virus (HBV)-derived peptide, Poly6, and alum adjuvants.
    Vaccine. 2025;47:126710.
    PubMed     Abstract available


  13. SU Q, Qiu F, Gao Z, Zhao Y, et al
    Long-term efficacy and anamnestic response of hepatitis B vaccine derived from Chinese hamster ovary cell after 18-20 years.
    Vaccine. 2025;47:126655.
    PubMed     Abstract available


    November 2024
  14. GRIGAS J, Spancerniene U, Simanavicius M, Pautienius A, et al
    Adaptive immune response to a wild boar-derived recombinant hepatitis e virus capsid protein challenge in pigs.
    Vaccine. 2024 Nov 30:126561. doi: 10.1016/j.vaccine.2024.126561.
    PubMed     Abstract available


  15. BERTHOUD TK, Ahmed T, Nadia W, Petrov I, et al
    A three antigen hepatitis B vaccine induces T cells to Pres1 and Pres2 which correlate with anti HBs antibody titers: An investigation into the immunological mechanisms contributing to high anti-HBs titers.
    Vaccine. 2024;43.
    PubMed     Abstract available


    October 2024
  16. NG AJJ, Teo DCH, Dorajoo SR, Yap AJY, et al
    Acute autoimmune hepatitis following COVID-19 mRNA vaccination: A population-based study using electronic health records in Singapore.
    Vaccine. 2024;42:126462.
    PubMed     Abstract available


  17. AREFAINE M, Johannessen A, Teklehaymanot T, Mihret A, et al
    A prospective, multicenter study of hepatitis B birth-dose vaccine with or without hepatitis B immunoglobulin in preventing mother-to-child transmission of hepatitis B virus in Ethiopia.
    Vaccine. 2024;42:126461.
    PubMed     Abstract available


  18. KANG S, Chung E, Hong C, Aziz AB, et al
    Raising the case of hepatitis E: Report from the 2nd international HEV symposium.
    Vaccine. 2024;42:126398.
    PubMed     Abstract available


    September 2024
  19. HOU X, Li N, Zhang H, Liu W, et al
    Hepatitis B virus infection and vaccination among people who use drugs in Xi'an, China.
    Vaccine. 2024;42:126259.
    PubMed     Abstract available


    August 2024
  20. DONG R, Luo Z, Shao J, Xue H, et al
    Understanding hepatitis E vaccination intention among women of childbearing-age: A theory-based cross-sectional study.
    Vaccine. 2024;42:126258.
    PubMed     Abstract available


  21. KANU FA, Freeland C, Nwokoro UU, Mohammed Y, et al
    Evaluation of interventions to improve timely hepatitis B birth dose vaccination among infants and maternal tetanus vaccination among pregnant women in Nigeria.
    Vaccine. 2024;42:126222.
    PubMed     Abstract available


    July 2024
  22. BESBASSI H, Elias G, Meysman P, Jansens H, et al
    Modeling antigen-specific T cell dynamics following Hepatitis B Vaccination indicates differences between conventional and regulatory T cell dynamics.
    Vaccine. 2024;42:126148.
    PubMed     Abstract available


  23. MESHRAM R, Kolte B, Gacche R
    Reverse vaccinology approach for identification of epitopes from E1 protein as peptide vaccine against HCV: A proof of concept.
    Vaccine. 2024 Jul 5:S0264-410X(24)00747-3. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


  24. KOUTSOUMPLI G, Stasiukonyte N, Hoogeboom BN, Daemen T, et al
    An in vitro CD8 T-cell priming assay enables epitope selection for hepatitis C virus vaccines.
    Vaccine. 2024 Jul 3:S0264-410X(24)00659-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    February 2024
  25. KOCHHAR S, Assis DN, Mack C, Izurieta HS, et al
    Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety data.
    Vaccine. 2024 Feb 16:S0264-410X(24)00021-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    January 2024
  26. SANTORO PE, Paladini A, Borrelli I, Amantea C, et al
    Vaccine-preventable diseases: Immune response in a large population of healthcare students.
    Vaccine. 2024 Jan 20:S0264-410X(24)00049-5. doi: 10.1016/j.vaccine.2024.
    PubMed     Abstract available


    December 2023
  27. DIONNE M, Sauvageau C, Kiely M, Dahhou M, et al
    School-based vaccination program against HPV and Hepatitis B: A longitudinal analysis of vaccine coverage between 2015 and 2021 in Quebec.
    Vaccine. 2023 Dec 2:S0264-410X(23)01419-6. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


    September 2023
  28. SANADA T, Oda Y, Ohashi C, Isotani K, et al
    Hybrid large hepatitis B surface protein composed of two viral genotypes C and D induces strongly cross-neutralizing antibodies.
    Vaccine. 2023 Sep 20:S0264-410X(23)01096-4. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  29. BIRNBAUM JA, Guttman D, Parulekar M, Omarufilo F, et al
    Eliminating hepatitis B vaccination disparities for West African immigrants.
    Vaccine. 2023 Sep 3:S0264-410X(23)01012-5. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


  30. SUSARLA SK, Gupta M, Uttam KG, Palkar S, et al
    Immunogenicity and safety of Havisure(TM) vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II/III, randomized, single blind, non-inferiority study.
    Vaccine. 2023 Sep 1:S0264-410X(23)01050-2. doi: 10.1016/j.vaccine.2023.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.